Tag:
Quality Problems
Latest Headlines
Latest Headlines
'Little things' blossomed into big QA trouble at J&J/McNeil
"When they leave, they take the routine with them," said an anonymous former J&J/McNeil worker of QA staff reductions following the company's acquisition of Pfizer Consumer Healthcare in 2006.
Hospira plant remediation stings company financials
Hospira ( $HSP ) has taken a big financial hit as a result of manufacturing deficiencies at its Rocky Mount, NC, plant. The hit--more than $1 billion in market capitalization, according to the
Quality meltdown still affects J&J financials, though Q3 sales are up
Johnson & Johnson ( $JNJ ) reports today in third-quarter financials that U.S. sales of OTC medicines were "significantly impacted" by the shutdown of McNeil's Consumer Healthcare manufacturing
WHO sends Panacea to remediation
It's time to revise the revenue projections at Panacea Biotech. The World Health Organization, following a late June manufacturing plant inspection, has removed three of the drugmaker's combination
McNeil consent decree quarantine helps J&J's bottom line
Last week's Johnson & Johnson/McNeil recall of musty smelling Tylenol and J&J's quarantine of the McNeil unit offer a fresh perspective on the interwoven nature of manufacturing, quality and
Mitsubishi Tanabe's 2M-unit recall follows QC lapse
A QC lapse has led Mitsubishi Tanabe Pharma to recall 2 million doses of three parenterals. The company says that for certain lots of the products, some aspects of pre-ship testing didn't make the
Weldon: Long ops fixes underway at J&J
J&J chief Bill Weldon says the company has checked quality operations at its 120 factories and realigned its supply chain to ensure the sharing of best practices, in light of its quality meltdown
FDA: McNeil QA OK'd use of bacteria-tainted ingredients in Tylenol
Add gram-negative bacterial contamination to the list of manufacturing woes cited last week in Johnson & Johnson/McNeil's recall of 1,500 lots of Children's Tylenol and other products. Bacterial
Regulator investigates Nanjing plant
China's State Food and Drug Administration (SFDA) is investigating quality concerns at a Simcere Pharmaceutical Group (NYSE: SCR ) plant in Nanjing. Production operations were suspended by the
